Beyond Weight Loss: Novo and Lilly Look to Expand Their GLP-1 Pipelines

While type 2 diabetes and obesity are the primary conditions currently treated with blockbuster GLP-1 drugs, Novo Nordisk and Eli Lilly aim to enter additional markets.